Signals, Powered By EquityPandit
Sun Pharmaceutical Industries has said that the US heath regulator has accepted biologics licence application (BLA) for tildrakizumab for the treatment of psoriasis.
Sun Pharma has said in a regulatory filing that “The FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. Tildrakizumab is an investigational IL-23p 19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis.”
Abhay Gandhi, Sun Pharma CEO-North America Business has said that “The acceptance of the regulatory filing by the US FDA marks a significant milestone as we seek to advance for tildrakizumab as a potential new treatment option for people who continue to struggle everyday with the chronic nature of psoriasis.”
